These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17210815

  • 1. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.
    Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, Conant K, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Marder K, Epstein LG.
    Arch Neurol; 2007 Jan; 64(1):97-102. PubMed ID: 17210815
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.
    Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, Schifitto G, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Epstein LG, Marder K.
    Neurology; 2004 Dec 14; 63(11):2084-90. PubMed ID: 15596754
    [Abstract] [Full Text] [Related]

  • 3. Markers of immune activation and viral load in HIV-associated sensory neuropathy.
    Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, McClernon DR, Conant K, Cohen B, Epstein LG, Kieburtz K, NEAD Consortium.
    Neurology; 2005 Mar 08; 64(5):842-8. PubMed ID: 15753420
    [Abstract] [Full Text] [Related]

  • 4. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.
    McArthur JC, McDermott MP, McClernon D, St Hillaire C, Conant K, Marder K, Schifitto G, Selnes OA, Sacktor N, Stern Y, Albert SM, Kieburtz K, deMarcaida JA, Cohen B, Epstein LG.
    Arch Neurol; 2004 Nov 08; 61(11):1687-96. PubMed ID: 15534180
    [Abstract] [Full Text] [Related]

  • 5. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults.
    Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, Gomo E, Butterworth AE, Pedersen BK, Ostrowski SR, Gerstoft J, Ullum H.
    AIDS; 2007 Nov 12; 21(17):2283-91. PubMed ID: 18090276
    [Abstract] [Full Text] [Related]

  • 6. Time-dependence of survival predictions based on markers of HIV disease. Swiss HIV Cohort Study.
    Perneger TV, Abrahamowicz M, Bartlett G, Yerly S.
    J Investig Med; 2000 May 12; 48(3):207-12. PubMed ID: 10822902
    [Abstract] [Full Text] [Related]

  • 7. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
    Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J.
    Clin Infect Dis; 2005 Mar 15; 40(6):853-8. PubMed ID: 15736019
    [Abstract] [Full Text] [Related]

  • 8. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 Mar 15; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

  • 9. Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia.
    Wachtman LM, Skolasky RL, Tarwater PM, Esposito D, Schifitto G, Marder K, McDermott MP, Cohen BA, Nath A, Sacktor N, Epstein LG, Mankowski JL, McArthur JC.
    Arch Neurol; 2007 Sep 15; 64(9):1264-72. PubMed ID: 17846264
    [Abstract] [Full Text] [Related]

  • 10. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J, Caelyx/Kaposi's Sarcoma Spanish Group.
    Clin Infect Dis; 2008 Aug 01; 47(3):410-7. PubMed ID: 18582203
    [Abstract] [Full Text] [Related]

  • 11. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.
    BMC Pediatr; 2007 Mar 17; 7():13. PubMed ID: 17367540
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children.
    McCoig C, Castrejón MM, Saavedra-Lozano J, Castaño E, Báez C, Lanier ER, Sáez-Llorens X, Ramilo O.
    Pediatr Infect Dis J; 2004 Feb 17; 23(2):114-8. PubMed ID: 14872175
    [Abstract] [Full Text] [Related]

  • 15. Characteristics and survival of HIV-infected patients not screened for hepatitis C virus infection in a hospital-based cohort.
    Bénet T, D'Oliveira A, Voirin N, Livrozet JM, Cotte L, Peyramond D, Chidiac C, Touraine JL, Fabry J, Trepo C, Allard R, Vanhems P.
    J Viral Hepat; 2007 Oct 17; 14(10):730-5. PubMed ID: 17875008
    [Abstract] [Full Text] [Related]

  • 16. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C, Lee S, Wong Kh, Cheng L, Lam M.
    HIV Med; 2007 Apr 17; 8(3):181-5. PubMed ID: 17461862
    [Abstract] [Full Text] [Related]

  • 17. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.
    J Infect Dis; 2007 Oct 01; 196(7):1044-52. PubMed ID: 17763327
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy.
    Savès M, Morlat P, Chêne G, Peuchant E, Pellegrin I, Bonnet F, Bernard N, Lacoste D, Salamon R, Beylot J.
    Clin Immunol; 2001 Jun 01; 99(3):347-52. PubMed ID: 11358430
    [Abstract] [Full Text] [Related]

  • 19. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M, Tozzi V, Lorenzini P, Forbici F, Narciso P, Ceccherini-Silberstein F, Trotta MP, Bertoli A, Liuzzi G, Marconi P, Mosti S, Perno CF, Antinori A.
    Antivir Ther; 2007 Jun 01; 12(2):163-8. PubMed ID: 17503658
    [Abstract] [Full Text] [Related]

  • 20. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study.
    AIDS; 2008 May 31; 22(9):1019-28. PubMed ID: 18520345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.